(NASDAQ: CRDL) Cardiol Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 364.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.09%.
Cardiol Therapeutics's earnings in 2025 is -$24,846,153.On average, 4 Wall Street analysts forecast CRDL's earnings for 2025 to be -$27,653,499, with the lowest CRDL earnings forecast at -$26,569,048, and the highest CRDL earnings forecast at -$28,466,838. On average, 5 Wall Street analysts forecast CRDL's earnings for 2026 to be -$49,657,359, with the lowest CRDL earnings forecast at -$82,278,343, and the highest CRDL earnings forecast at -$24,793,697.
In 2027, CRDL is forecast to generate -$13,975,424 in earnings, with the lowest earnings forecast at -$20,569,586 and the highest earnings forecast at -$10,101,136.